Research on a vaccine targeting Staphylococcus aureus evasion factors, specifically SpA and LukAB, has shown promise in restricting infection in minipig models. The vaccine's development is part of a broader effort to understand and counter the bacterium's immune evasion strategies. Studies on Staphylococcus aureus infection and vaccine efficacy are ongoing, exploring various aspects of the bacterium's behavior and interactions with the host immune system.